All news

AbbVie lifts 2026 neuroscience outlook to

Alpha Vantage · TradingView · · AI-summarised by FinFlash

AbbVie's neuroscience segment generated $3.39 billion in third-quarter revenue, up 19.5% year over year, driven by Vraylar, Ubrelvy, Qulipta and Botox Therapeutic. The company raised its 2026 neuroscience sales outlook to

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.